These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
231 related articles for article (PubMed ID: 17768754)
1. Quantifying synergism/antagonism using nonlinear mixed-effects modeling: a simulation study. Boik JC; Newman RA; Boik RJ Stat Med; 2008 Mar; 27(7):1040-61. PubMed ID: 17768754 [TBL] [Abstract][Full Text] [Related]
2. Interaction index and different methods for determining drug interaction in combination therapy. Lee JJ; Kong M; Ayers GD; Lotan R J Biopharm Stat; 2007; 17(3):461-80. PubMed ID: 17479394 [TBL] [Abstract][Full Text] [Related]
4. Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design. Chou TC; Motzer RJ; Tong Y; Bosl GJ J Natl Cancer Inst; 1994 Oct; 86(20):1517-24. PubMed ID: 7932806 [TBL] [Abstract][Full Text] [Related]
5. Evaluation of combination chemotherapy: integration of nonlinear regression, curve shift, isobologram, and combination index analyses. Zhao L; Wientjes MG; Au JL Clin Cancer Res; 2004 Dec; 10(23):7994-8004. PubMed ID: 15585635 [TBL] [Abstract][Full Text] [Related]
6. Determining the error of dose estimates and minimum and maximum acceptable concentrations from assays with nonlinear dose-response curves. Gottschalk PG; Dunn JR Comput Methods Programs Biomed; 2005 Dec; 80(3):204-15. PubMed ID: 16256244 [TBL] [Abstract][Full Text] [Related]
7. Design and sample size for evaluating combinations of drugs of linear and loglinear dose-response curves. Fang HB; Tian GL; Li W; Tan M J Biopharm Stat; 2009 Jul; 19(4):625-40. PubMed ID: 20183430 [TBL] [Abstract][Full Text] [Related]
8. Experimental design and interaction analysis of combination studies of drugs with log-linear dose responses. Fang HB; Ross DD; Sausville E; Tan M Stat Med; 2008 Jul; 27(16):3071-83. PubMed ID: 18186545 [TBL] [Abstract][Full Text] [Related]
9. Concepts of synergism and antagonism. Merlin JL Anticancer Res; 1994; 14(6A):2315-9. PubMed ID: 7825965 [TBL] [Abstract][Full Text] [Related]
10. Amphibolic drug combinations: the design of selective antimetabolite protocols based upon the kinetic properties of multienzyme systems. Jackson RC Cancer Res; 1993 Sep; 53(17):3998-4003. PubMed ID: 8358729 [TBL] [Abstract][Full Text] [Related]
11. Evaluating response to antineoplastic drug combinations in tissue culture models. Reynolds CP; Maurer BJ Methods Mol Med; 2005; 110():173-83. PubMed ID: 15901935 [TBL] [Abstract][Full Text] [Related]
12. Towards a mechanism-based analysis of pharmacodynamic drug-drug interactions in vivo. Jonker DM; Visser SA; van der Graaf PH; Voskuyl RA; Danhof M Pharmacol Ther; 2005 Apr; 106(1):1-18. PubMed ID: 15781119 [TBL] [Abstract][Full Text] [Related]
13. Nonlinear mixed effects to improve glucose minimal model parameter estimation: a simulation study in intensive and sparse sampling. Denti P; Bertoldo A; Vicini P; Cobelli C IEEE Trans Biomed Eng; 2009 Sep; 56(9):2156-66. PubMed ID: 19380266 [TBL] [Abstract][Full Text] [Related]
14. Simultaneous confidence bands for nonlinear regression models with application to population pharmacokinetic analyses. Gsteiger S; Bretz F; Liu W J Biopharm Stat; 2011 Jul; 21(4):708-25. PubMed ID: 21516565 [TBL] [Abstract][Full Text] [Related]
15. Analysis of multidrug effects by parameter method. Zheng QS; Sun RY Zhongguo Yao Li Xue Bao; 1998 May; 19(3):232-7. PubMed ID: 10375732 [TBL] [Abstract][Full Text] [Related]
16. A generalized response surface model with varying relative potency for assessing drug interaction. Kong M; Lee JJ Biometrics; 2006 Dec; 62(4):986-95. PubMed ID: 17156272 [TBL] [Abstract][Full Text] [Related]
17. Fitting models for the joint action of two drugs using SAS. Whitehead A; Whitehead J; Todd S; Zhou Y; Smith MK Pharm Stat; 2008; 7(4):272-84. PubMed ID: 17979217 [TBL] [Abstract][Full Text] [Related]
18. Estrogenic activity of ternary UV filter mixtures in fish (Pimephales promelas) - an analysis with nonlinear isobolograms. Kunz PY; Fent K Toxicol Appl Pharmacol; 2009 Jan; 234(1):77-88. PubMed ID: 18992764 [TBL] [Abstract][Full Text] [Related]
19. Profile likelihood-based confidence intervals using Monte Carlo integration for population pharmacokinetic parameters. Funatogawa T; Funatogawa I; Yafune A J Biopharm Stat; 2006; 16(2):193-205. PubMed ID: 16584067 [TBL] [Abstract][Full Text] [Related]
20. A mathematical approach to study combined effects of toxicants in vitro: evaluation of the Bliss independence criterion and the Loewe additivity model. Goldoni M; Johansson C Toxicol In Vitro; 2007 Aug; 21(5):759-69. PubMed ID: 17420112 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]